CONNECT WITH US
HealthTech

HealthTech

Malaria vaccine shows 87% efficacy in clinical trial

Medical Xpress logo

Published on

Add as a preferred source on Google
Malaria vaccine shows 87% efficacy in clinical trial

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The novel, genetically attenuated whole-parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.

Among 22 participants exposed to a controlled malaria challenge 12 to 16 weeks after their last dose of the vaccine, all seven placebo recipients became infected, while only two of 15 vaccinated individuals developed an infection. All infected participants were safely and promptly treated. In addition, the vaccine was safe and well tolerated in the vaccinated participants.

These findings were presented today at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C. They were reported by Dr. Sean C. Murphy, professor of laboratory medicine and pathology at the University of Washington School of Medicine and medical director of the Department of Laboratories at Seattle Children's Hospital.

The recently completed trial was conducted by UW Medicine and its partners as part of the Infectious Diseases Clinical Research Consortium, or IDCRC.

The trial began enrollment in the summer of 2025. The study's co-principal investigators, along with Murphy, are Dr. Jim Kublin of the Fred Hutch Cancer Center's Vaccine and Infectious Disease Division and Dr. R. Scott McClelland, professor of medicine, epidemiology and global health at UW School of Medicine, who led clinical site operations at Harborview Medical Center's Virology Research Clinic.

Because there are over 600,000 deaths worldwide each year from malaria, vaccines that completely block infection—rather than just reduce symptom severity—are urgently needed.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.